Friday, 03 Apr 2020

You are here

RheumNow Week in Review - 15 April 2016

Video recap of highlights from this week at

  1. In patients with connective tissue disease and interstitial lung disease (ILD): NSIP, UIP, OP (use to be BOOP), LIP are NOT diagnoses - these are lung injury patterns with clinical associations and correlations.  (Courtesy of Dr. Aryeh Fischer at the ARTHROS W. Virgina State Rheumatology Meeting)
  2. UIP (Usual interstitial pneumonia) is best diagnosed by HRCT; appears as honeycombing; and is the most common form of ILD. It is also the most common cause of ILD in rheumatoid arthritis and second most common in PSS and other CTD.
  3. NSIP (nonspecific interstitial pneumonitis): shows as ground glass opacities; most common ILD pattern in PSS and other CTD.  NSIP has better survival than UIP.
  4. Who should get HRCT after CXR and PFTs? Each of the following increase the likelihood of having significant ILD: consider in Men, smokers, CCP+, RA patients. CCP+ is independent risk factor for ILD.
  5. The majority of PSS patients will have ILD (fibrotic NSIP is most common). ILD is the leading cause of death in PSS.
  6. In 658 hospitalized PSS patients, there were 29 deaths. The risk factors associated with death was ascertained; - higher risk with high BUN, history of aspiration, low Hgb, non-SSc lung disease
  7. In an IBD cohort study, perioperative MTX use was not associated with an increase in post-operative  complications or sepsis in IBD pts having abdominal surgery. 
  8. Colchicine once daily is equivalent to twice daily dosing in preventing attacks with Familial Meditteranean Fever 
  9. A metanalysis of 4 RCT using rituximab (RTX) in Sjogren’s syndrome:  276 patients saw that RTX had no effect on Schirmers test, fatigue, ESSDAI & SF36 after 24 weeks.  
  10.  Surgical Management of Spinal Stenosis - To Fuse or Not To Fuse?
  11. Lupus Patients Genomically Stratified to Explain Treatment Responses 
  12. Population-Based TB Risk and Prevention with RA and Biologics
  13. A Rocky Start for Biosimilar Inflectra?
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Pandemic Numbers (4.3.20)

Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week.   Be sure to check out:

CDC: Impact of Underlying Health Conditions Among COVID-19 Patients

The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections.  Below are experts from that report.

TeleRheumatology - a TED Talk by Alvin Wells, MD

RheumNow Live 2020 featured a series of shorter STEP (TED-like) talks. This one features Dr. Alvin Wells discussing the opportunities and new paradigms encumbent with telemedicine in rheumatology.

RheumNow Podcast – New World Order (3.27.20)

Dr. Jack Cush reviews the news and COVID developments from this past week.

Global Rheumatology Alliance Registry Will Study COVID-19

In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.